Pharmaceutics

This page contains key pharmaceutical news on drug recalls, FDA clearance, safety communications and research. In cardiology, key pharmaceutic agents include antiplatelet therapies, anticoagulants, hypertension drugs, and drugs for heart failure and arrhythmias.   

RSS icon

Largest U.S. pharmacist association has major concerns about government labeling it a biased special interest group

The American Pharmacists Association is being labeled as a biased special interest group under new rules for the CDC Advisory Committee on Immunization Practices, a move that seems to be politically motivated when APhA did not support changes in COVID vaccines earlier this year. 

ESC Congress 2022 European Society of Cardiology

The most anticipated trials at ESC 2025

The European Society of Cardiology 2025 congress includes 10 Hot Line sessions and 28 late-breaking science sessions to showcase the latest science.

Tirzepatide, a once-weekly injectable dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide receptor agonist (GLP-1), has been approved by the U.S. Food & Drug Administration (FDA) for improving glycemic control among adults with type 2 diabetes. The medication, sold by Eli Lilly and Company under the name Mounjaro, will be available in six different doses and come in an auto-injector pen.

Tirzepatide demonstrates cardiovascular protection in head-to-head trial with dulaglutide

Tirzepatide met the primary endpoint of non-inferiority versus dulaglutide, with an 8% lower rate of MACE events included cardiovascular death, heart attack or stroke, while delivering greater reductions in A1C and weight.

cardiologists heart doctors heart research heart data

Colchicine reduces risk of some TAVR complications

Giving colchicine to patients prior to TAVR may reduce the risk of certain conduction disturbances, according to new research published in the Journal of the American Heart Association. It does not, however, improve survival.

pharmaceutical drug approval process

New drug candidate for AFib fails in first-in-human trial—in fact, it made matters worse

Researchers had thought 2-HOBA might reduce the risk of AFib recurrence after catheter ablation procedures. What they found, however, was that treatment with the compound was actually harmful for patients instead of helpful. 

Compensation for U.S. cardiologists is up across the board, according to a recent survey published by MedAxiom, an American College of Cardiology company. The report identified similar trends for cardiovascular surgeons, highlighting the country’s high demand for all heart specialists in 2024 and beyond.

New gene therapy for rare heart condition gains FDA’s fast track designation

Catecholaminergic polymorphic ventricular tachycardia is a rare, potentially fatal heart rhythm disorder. A new gene therapy candidate from Solid Biosciences is now one step closer to FDA approval. 

Thumbnail

Widespread use of polypills could prevent up to 72 million heart disease deaths

Targeting high-risk patients with single-pill combination therapies, also known as polypills, could change healthcare on a global scale, according new data published in the Journal of the American College of Cardiology. 

Medtronic’s MiniMed 780G automated insulin delivery system

Medtronic receives key approvals for automated insulin pump

The company's automated insulin pump can now be used to treat more patients thanks to an expanded CE mark approval. Could updates from the FDA be next?

Displaying 33 - 40 of 393
Design by Adaptive Theme